Bausch + Lomb Corporation (BLCO.TO) TSX
20.60
-0.69(-3.24%)
Currency In CAD
- General
- Statistics
- Historical Data
- Profile
- Financials
Bausch + Lomb Corporation
Address
520 Applewood Crescent
Vaughan, ON L4K 4B4
Canada
Phone
905 695 7700
Website
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Employees
13500
First IPO Date
May 06, 2022
Key Executives
| Name | Title | Pay | Year Born |
| Brenton L. Saunders | Chief Executive Officer & Chairman | 7.75M | 1970 |
| Andrew Stewart | President of Global Pharmaceuticals & International Consumer | 1.72M | 1976 |
| Yehia Hashad | Executive Vice President of Research & Development and Chief Medical officer | 1.99M | 1968 |
| A. Robert D. Bailey | Executive Vice President & Chief Legal Officer | 2.03M | 1963 |
| Osama A. Eldessouky | Executive Vice President & Chief Financial Officer | 2.47M | 1972 |
| Frederick J. Munsch | Senior Vice President, Controller & Chief Accounting Officer | 0 | 1970 |
| Alan Waterhouse CPFA | Executive Vice President and Chief Supply Chain & Operations Officer | 0 | 1960 |
| Jonathon L. Kellerman | Chief Compliance Officer | 0 | N/A |
| Crawford | Chief Communications Officer | 0 | N/A |
| George Gadkowski | Vice President & Head of Investor Relations & Business Insights | 0 | N/A |
Description
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
